Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Parabilis Medicines, Inc.
Alliance for Clinical Trials in Oncology
AstraZeneca
Agenus Inc.
National Cancer Institute (NCI)
Aveni Foundation
ViroMissile, Inc.
Dana-Farber Cancer Institute
Washington University School of Medicine
University of Florida
Essen Biotech
Angiex, Inc.
University of Nebraska
Adela, Inc
Tanabe Pharma America, Inc.
AVM Biotechnology Inc
Pfizer
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
3B Pharmaceuticals GmbH
Fudan University
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Institut Bergonié
NextPoint Therapeutics, Inc.
OncoC4, Inc.
Tempus AI
Mayo Clinic